Metabolic disease due to other fatty acid oxidation disorder Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

1 event

Jun 2020

Dojolvi: FDA approved

DOJOLVI is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Dojolvi

Ultragenyx Pharmaceutical, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Dojolvi

(triheptanoin)Orphan drug

Ultragenyx Pharmaceutical, Inc.

Medium-chain Triglyceride [EPC]

12.1 Mechanism of Action Triheptanoin is a medium-chain triglyceride consisting of three odd-chain 7-carbon length fatty acids (heptanoate) that provi...

Approved Jun 2020FDA label ↗

View full treatment details on disease page →